Institution,Word,Count
Oxford,Humans,10878
Oxford,Female,4183
Oxford,Male,4047
Oxford,Animals,4010
Oxford,Middle Aged,2488
Oxford,Mice,2064
Oxford,Aged,2062
Oxford,Adult,2002
Oxford,Models,1748
Oxford,Cell Line,1263
Oxford,Molecular,1017
Oxford,Genetic,1011
Oxford,Gene Expression Regulation,1006
Oxford,Mutation,961
Oxford,Risk Factors,929
Oxford,Tumor,907
Oxford,Polymorphism,847
Oxford,Magnetic Resonance Imaging,822
Oxford,Signal Transduction,789
Oxford,80 and over,789
Oxford,Neoplasms,786
Oxford,Receptors,774
Oxford,Prospective Studies,763
Oxford,Single Nucleotide,751
Oxford,Young Adult,714
Oxford,Molecular Sequence Data,689
Oxford,RNA,683
Oxford,Case-Control Studies,640
Oxford,DNA,636
Oxford,Protein Binding,631
Oxford,Treatment Outcome,603
Oxford,Cultured,589
Oxford,Genetic Predisposition to Disease,583
Oxford,Protein Structure,582
Oxford,Great Britain,575
Oxford,Cohort Studies,574
Oxford,Prognosis,569
Oxford,Reproducibility of Results,546
Oxford,Inbred C57BL,543
Oxford,Human,537
Oxford,Computer-Assisted,530
Oxford,Cells,528
Oxford,Biological,515
Oxford,Biomarkers,510
Oxford,Time Factors,510
Oxford,Antigens,502
Oxford,Genome-Wide Association Study,487
Oxford,Amino Acid Sequence,486
Oxford,Tertiary,478
Oxford,Adolescent,447
Oxford,Cell Proliferation,445
Oxford,Breast Neoplasms,426
Oxford,Phenotype,422
Oxford,Animal,421
Oxford,Neoplastic,417
Oxford,Randomized Controlled Trials as Topic,416
Oxford,Crystallography,409
Oxford,Research Design,407
Oxford,Brain,406
Oxford,Microscopy,405
Oxford,X-Ray,398
Oxford,Genome,390
Oxford,Genotype,389
Oxford,Prostatic Neoplasms,385
Oxford,Follow-Up Studies,382
Oxford,Child,381
Oxford,Colorectal Neoplasms,379
Oxford,Chromosomes,373
Oxford,Cell Differentiation,371
Oxford,Algorithms,353
Oxford,Disease Models,351
Oxford,Antineoplastic Agents,351
Oxford,T-Lymphocytes,349
Oxford,Knockout,348
Oxford,Predictive Value of Tests,344
Oxford,Sequence Analysis,338
Oxford,Alleles,332
Oxford,Risk Assessment,331
Oxford,Binding Sites,330
Oxford,Carcinoma,328
Oxford,Antibodies,320
Oxford,Protein Conformation,312
Oxford,Base Sequence,312
Oxford,Sensitivity and Specificity,307
Oxford,Phosphorylation,304
Oxford,Stroke,304
Oxford,DNA-Binding Proteins,299
Oxford,Myocardium,291
Oxford,Messenger,282
Oxford,Transcription Factors,281
Oxford,Fluorescence,281
Oxford,Incidence,278
Oxford,Molecular Structure,275
Oxford,Gene Expression Profiling,275
Oxford,Transcription,269
Oxford,Nuclear Proteins,268
Oxford,Genes,266
Oxford,Retrospective Studies,264
Oxford,Membrane Proteins,263
Oxford,Apoptosis,261
Oxford,England,258
Oxford,Infant,258
Oxford,Rats,257
Oxford,Body Mass Index,253
Oxford,Statistical,250
Oxford,Immunohistochemistry,248
Oxford,Inflammation,247
Oxford,Transgenic,245
Oxford,Severity of Illness Index,244
Oxford,DNA Damage,241
Oxford,Europe,237
Oxford,HEK293 Cells,236
Oxford,Genetic Variation,236
Oxford,Disease Progression,231
Oxford,Magnetic Resonance Spectroscopy,227
Oxford,Surveys and Questionnaires,226
Oxford,Preschool,225
Oxford,Blotting,225
Oxford,DNA Repair,224
Oxford,Flow Cytometry,224
Oxford,RNA Interference,223
Oxford,Protein-Serine-Threonine Kinases,222
Oxford,Western,221
Oxford,Cell Survival,221
Oxford,Computer Simulation,221
Oxford,MicroRNAs,217
Oxford,Histones,216
Oxford,Image Processing,214
Oxford,Monoclonal,213
Oxford,HeLa Cells,208
Oxford,Promoter Regions,208
Oxford,Neoplasm,208
Oxford,Cardiovascular Diseases,207
Oxford,Clinical Trials as Topic,207
Oxford,Kinetics,207
Oxford,Tomography,206
Oxford,Evolution,205
Oxford,Leukemia,202
Oxford,Databases,201
Oxford,Neovascularization,201
Oxford,Cross-Sectional Studies,201
Oxford,Cell Cycle Proteins,200
Oxford,Structure-Activity Relationship,199
Oxford,Gene Frequency,195
Oxford,Genetic Loci,194
Oxford,Radiotherapy,192
Oxford,European Continental Ancestry Group,191
Oxford,Newborn,191
Oxford,Developmental,190
Oxford,Receptor,188
Oxford,Cell Hypoxia,188
Oxford,Immunity,188
Oxford,Catalysis,188
Oxford,Imaging,186
Oxford,CD8-Positive T-Lymphocytes,185
Oxford,Hypoxia-Inducible Factor 1,184
Oxford,Substrate Specificity,182
Oxford,Oligonucleotide Array Sequence Analysis,179
Oxford,Cell Movement,176
Oxford,Pregnancy,175
Oxford,Diabetes Mellitus,174
Oxford,Secondary,173
Oxford,Proteins,172
Oxford,Cytokines,172
Oxford,Phylogeny,172
Oxford,Peptides,171
Oxford,Oxygen,170
Oxford,DNA Mutational Analysis,170
Oxford,HIV Infections,169
Oxford,Small Interfering,169
Oxford,Recombinant Proteins,169
Oxford,Stereoisomerism,169
Oxford,Proportional Hazards Models,167
Oxford,Lymphocyte Activation,167
Oxford,Antineoplastic Combined Chemotherapy Protocols,166
Oxford,Catalytic Domain,165
Oxford,Obesity,165
Oxford,Pathologic,164
Oxford,Odds Ratio,164
Oxford,Gene Expression,164
Oxford,Enzyme Inhibitors,164
Oxford,Bacterial,162
Oxford,Blood Pressure,162
Oxford,Repressor Proteins,161
Oxford,Chromatin,161
Oxford,Sequence Alignment,160
Oxford,Contrast Media,159
Oxford,Protein Kinase Inhibitors,159
Oxford,Type 2,158
Oxford,Chronic,157
Oxford,Risk,155
Oxford,Cell Membrane,155
Oxford,Age Factors,155
Oxford,Proto-Oncogene Proteins,154
Oxford,Prevalence,154
Oxford,Myocardial Infarction,152
Oxford,Inbred BALB C,152
Oxford,Diet,150
Oxford,Heart,150
Oxford,Dose-Response Relationship,149
Oxford,Tumor Suppressor Protein p53,149
Oxford,Escherichia coli,148
Oxford,Oxidation-Reduction,148
Oxford,T-Cell,148
Oxford,Ligands,147
Oxford,CD4-Positive T-Lymphocytes,147
Oxford,Coronary Artery Disease,146
Oxford,Chromosome Mapping,146
Oxford,Neoplasm Staging,146
Oxford,X-Ray Computed,145
Oxford,Disease-Free Survival,144
Oxford,Practice Guidelines as Topic,143
Oxford,Guidelines as Topic,143
Oxford,Publishing,142
Oxford,Chromatography,142
Oxford,Brain Mapping,142
Oxford,Antigen,141
Oxford,Sex Factors,141
Oxford,Macrophages,140
Oxford,Multivariate Analysis,138
Oxford,Hepatitis C,138
Oxford,Image Interpretation,138
Oxford,Cine,137
Oxford,Experimental,136
Oxford,Checklist,136
Oxford,Data Interpretation,136
Oxford,Cholesterol,135
Oxford,Real-Time Polymerase Chain Reaction,134
Oxford,HIV-1,134
Oxford,Image Enhancement,133
Oxford,Intracellular Signaling Peptides and Proteins,132
Oxford,DNA Replication,132
Oxford,Protein Processing,131
Oxford,alpha Subunit,131
Oxford,Post-Translational,131
Oxford,Prostatectomy,130
Oxford,Analysis of Variance,130
Oxford,DNA Methylation,130
Oxford,China,130
Oxford,Reverse Transcriptase Polymerase Chain Reaction,128
Oxford,Kaplan-Meier Estimate,128
Oxford,Carrier Proteins,128
Oxford,Hematopoietic Stem Cells,128
Oxford,Cell Transformation,127
Oxford,Drug Resistance,126
Oxford,Exons,126
Oxford,Energy Metabolism,125
Oxford,Lung Neoplasms,125
Oxford,Dendritic Cells,125
Oxford,DNA Breaks,125
Cambridge,EXPRESSION,204
Cambridge,RISK,179
Cambridge,GENOME-WIDE ASSOCIATION,159
Cambridge,IN-VIVO,146
Cambridge,CANCER,144
Cambridge,GENE-EXPRESSION,143
Cambridge,BREAST-CANCER,120
Cambridge,Humans,104
Cambridge,GENE,102
Cambridge,PROTEIN,102
Cambridge,POPULATION,97
Cambridge,CELLS,96
Cambridge,DIFFERENTIATION,87
Cambridge,METAANALYSIS,86
Cambridge,IDENTIFICATION,85
Cambridge,ASSOCIATION,81
Cambridge,BINDING,80
Cambridge,ACTIVATION,75
Cambridge,MORTALITY,74
Cambridge,SURVIVAL,72
Cambridge,WOMEN,69
Cambridge,MODEL,68
Cambridge,VARIANTS,66
Cambridge,DISEASE,63
Cambridge,PARTON DISTRIBUTIONS,63
Cambridge,COHORT,62
Cambridge,OBESITY,60
Cambridge,breast cancer,57
Cambridge,MICE,57
Cambridge,LUNG-CANCER,56
Cambridge,Hadron-Hadron Scattering,55
Cambridge,POSITRON-EMISSION-TOMOGRAPHY,54
Cambridge,IN-VITRO,54
Cambridge,LHC,54
Cambridge,COMPLEX,54
Cambridge,LOCI,53
Cambridge,CARDIOVASCULAR-DISEASE,51
Cambridge,RECEPTOR,51
Cambridge,POLYMORPHISMS,48
Cambridge,PROSTATE-CANCER,48
Cambridge,MUTATIONS,48
Cambridge,SUSCEPTIBILITY,48
Cambridge,Animals,47
Cambridge,RISK-FACTORS,45
Cambridge,CARCINOMA,45
Cambridge,COLORECTAL-CANCER,44
Cambridge,NUTRITION,42
Cambridge,EVOLUTION,42
Cambridge,GROWTH,42
Cambridge,NATURAL-PRODUCTS,42
Cambridge,PROTEINS,41
Cambridge,SEQUENCE,41
Cambridge,Female,41
Cambridge,GENOME,41
Cambridge,CHEMISTRY,39
Cambridge,SACCHAROMYCES-CEREVISIAE,39
Cambridge,STEM-CELLS,39
Cambridge,TRIAL,39
Cambridge,inflammation,39
Cambridge,METABOLIC SYNDROME,39
Cambridge,MRI,38
Cambridge,PET,38
Cambridge,DNA,38
Cambridge,EMBRYONIC STEM-CELLS,38
Cambridge,OVARIAN-CANCER,36
Cambridge,PROGRESSION,36
Cambridge,GENES,36
Cambridge,PATHWAY,36
Cambridge,INHIBITION,36
Cambridge,PHYSICAL-ACTIVITY,36
Cambridge,FAMILY,36
Cambridge,SUSCEPTIBILITY LOCI,36
Cambridge,COMMON VARIANTS,36
Cambridge,DIAGNOSIS,35
Cambridge,TRANSCRIPTION,33
Cambridge,BRCA2,33
Cambridge,BODY-MASS INDEX,33
Cambridge,SPECTROSCOPY,33
Cambridge,PATTERNS,33
Cambridge,prostate cancer,32
Cambridge,BLOOD-PRESSURE,32
Cambridge,atherosclerosis,32
Cambridge,NMR,31
Cambridge,PROLIFERATION,30
Cambridge,MEN,30
Cambridge,APOPTOSIS,30
Cambridge,CONFER SUSCEPTIBILITY,30
Cambridge,DERIVATIVES,30
Cambridge,CRYSTAL-STRUCTURE,30
Cambridge,DESIGN,29
Cambridge,RECOGNITION,29
Cambridge,Physical activity,29
Cambridge,DRUG DISCOVERY,29
Cambridge,MOUSE,27
Cambridge,BREAST,27
Cambridge,PATHWAYS,27
Cambridge,VALIDITY,27
Cambridge,THERAPY,27
Cambridge,SUSCEPTIBILITY LOCUS,27
Cambridge,EPIC-NORFOLK,27
Cambridge,HADRON COLLIDERS,27
Cambridge,MANAGEMENT,27
Cambridge,RESISTANCE,27
Cambridge,ESTROGEN-RECEPTOR,27
Cambridge,HYPOXIA,27
Cambridge,HEALTH,27
Cambridge,CELL-CYCLE,27
Cambridge,UNITED-STATES,27
Cambridge,mitosis,27
Cambridge,ADULTS,27
Cambridge,Neoplasms,26
Cambridge,KINETICS,26
Cambridge,MECHANISM,26
Cambridge,Inflammation,25
Cambridge,STABILITY,25
Cambridge,PREDICTION,24
Cambridge,ALZHEIMERS-DISEASE,24
Cambridge,REVEALS,24
Cambridge,CHROMATIN,24
Cambridge,ATLAS,24
Cambridge,ENDOTHELIAL-CELLS,24
Cambridge,MICROARRAY DATA,24
Cambridge,MITOTIC SPINDLE,24
Cambridge,ORGANIC-SYNTHESIS,24
Cambridge,C-MYC,24
Cambridge,NF-KAPPA-B,24
Cambridge,Breast Neoplasms,24
Cambridge,EPITHELIAL-CELLS,24
Cambridge,DOMAIN,24
Cambridge,DYNAMICS,24
Cambridge,EPIC,24
Cambridge,cancer,24
Cambridge,TRANSCRIPTION FACTOR,24
Cambridge,INSULIN-RESISTANCE,24
Cambridge,CORONARY-HEART-DISEASE,24
Cambridge,RANDOMIZED CONTROLLED-TRIAL,24
Cambridge,LOCALIZATION,24
Cambridge,ADENOCARCINOMA,24
Cambridge,INSULIN,23
Cambridge,HERA,23
Cambridge,BEHAVIOR,23
Cambridge,RESOLUTION,23
Cambridge,CLASSIFICATION,23
Cambridge,Male,23
Cambridge,natural products,22
Cambridge,ACUTE MYELOID-LEUKEMIA,22
Cambridge,COLLISIONS,22
Cambridge,CHRONIC MYELOID-LEUKEMIA,21
Cambridge,BRCA1,21
Cambridge,HUMAN GENOME,21
Cambridge,TISSUE,21
Cambridge,PHOSPHORYLATION,21
Cambridge,OXIDATIVE STRESS,21
Cambridge,ALLELES,21
Cambridge,COMPLEXES,21
Cambridge,BLADDER-CANCER,21
Cambridge,PREVALENCE,21
Cambridge,HEART-DISEASE,21
Cambridge,CENTRAL-NERVOUS-SYSTEM,21
Cambridge,COLON-CANCER,21
Cambridge,Middle Aged,21
Cambridge,ESCHERICHIA-COLI,21
Cambridge,PANCREATIC-CANCER,21
Cambridge,Atherosclerosis,21
Cambridge,CAENORHABDITIS-ELEGANS,21
Cambridge,MOLECULES,21
Cambridge,DOUBLE-STRAND BREAKS,21
Cambridge,TUMORS,21
Cambridge,CHEMOTHERAPY,21
Cambridge,METHYLATION,21
Cambridge,Mice,21
Cambridge,MYOCARDIAL-INFARCTION,21
Cambridge,HOMOLOGOUS RECOMBINATION,21
Cambridge,EPIDEMIOLOGY,21
Cambridge,ATHEROSCLEROSIS,21
Cambridge,MAGNETIC-RESONANCE-SPECTROSCOPY,21
Cambridge,SOCIOECONOMIC-STATUS,21
Cambridge,WATER,20
Cambridge,DEGRADATION,20
Cambridge,Aged,20
Cambridge,FILMS,20
Cambridge,CELL-DEATH,20
Cambridge,AQUEOUS-SOLUTION,20
Cambridge,SYSTEM,19
Cambridge,PARTICLES,19
Cambridge,PROGENITORS,19
Cambridge,DISCOVERY,19
Cambridge,TRANSPORT,19
Cambridge,REPLICATION,18
Cambridge,SOMATIC MUTATIONS,18
Cambridge,chromatin,18
Cambridge,GENETICS,18
Cambridge,NANOPARTICLES,18
Cambridge,BIOLOGY,18
Cambridge,KINASE,18
Cambridge,CALIBRATION,18
Cambridge,DNA-BINDING,18
Cambridge,Type 2 diabetes,18
Cambridge,HELICOBACTER-PYLORI,18
Cambridge,cohort study,18
Cambridge,POLYMERS,18
Cambridge,PROMOTER,18
Cambridge,DNA-DAMAGE RESPONSE,18
Cambridge,CONSUMPTION,18
Cambridge,GERMLINE MUTATIONS,18
Cambridge,ENGLAND,18
Cambridge,MOUSE MODEL,18
Cambridge,RECOMBINATION,18
Cambridge,DNA-REPAIR,18
Cambridge,DIABETES-MELLITUS,18
Cambridge,LESIONS,18
Cambridge,SERUM,18
Cambridge,GROWTH-FACTOR,18
Cambridge,ovarian cancer,18
Cambridge,SYSTEMIC-LUPUS-ERYTHEMATOSUS,18
Cambridge,DROSOPHILA,18
Cambridge,TUMOR-SUPPRESSOR,18
Cambridge,PROGENITOR CELLS,18
Cambridge,POSTMENOPAUSAL WOMEN,18
Cambridge,LIVING CELLS,18
Cambridge,MASS-SPECTROMETRY,18
Cambridge,PHENOTYPE,18
Cambridge,BRCA2 MUTATION CARRIERS,18
Cambridge,CONSORTIUM,18
Cambridge,SMALL-MOLECULE,18
Cambridge,OVEREXPRESSION,18
Cambridge,TRANSLOCATION,18
Cambridge,RNA,18
Cambridge,Mitochondria,17
Cambridge,TARGETS,17
Cambridge,NITRIC-OXIDE,17
Cambridge,ABSORPTION,17
Cambridge,C-REACTIVE PROTEIN,17
Cambridge,SYSTEMS,17
Cambridge,LIGHT-SCATTERING,17
Cambridge,SURFACES,17
Cambridge,LIGAND,17
Cambridge,Cohort study,17
Cambridge,SUPERGAUGE TRANSFORMATIONS,17
Cambridge,flow chemistry,17
Cambridge,Biomarkers,17
Cambridge,MICROREACTOR,17
Cambridge,Models,17
Cambridge,Barrett's oesophagus,17
Cambridge,BIOMARKERS,17
Cambridge,REACTOR,16
Cambridge,INHIBITORS,16
Cambridge,COMPOSITES,16
Cambridge,MECHANICAL-PROPERTIES,16
Cambridge,LIGAND-BINDING,15
